Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy
IMPACT: Improving Management of Advanced Colorectal Tumours
Pre-operative radiation for pancreatic cancer
Second-line and beyond in mCRC: Optimising the benefit and reducing the risk
Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus 6 months
Colorectal cancer in the young: What do we know and what can we do?
Rectal cancers: Positioning of watchful waiting and minimally invasive procedures
Beyond second-line therapy: New hope for mCRC patients in Egypt
Multi-target kinase inhibitors: From data to practice
Highlights from IGILUC 2019
Advanced gastric cancer: What do we know and what we must know?
Novel approaches and future strategies in management of upper GI tumours